- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XOMA ROYALTY CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 17:10 | Ligand snaps up fellow biotech royalty aggregator Xoma for $739M | 2 | FiercePharma | ||
| 16:30 | XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday | 1 | Benzinga.com | ||
| 13:59 | Ligand To Acquire XOMA Royalty For Around $739 Mln, Both Stocks Up In Pre-market | 1 | RTTNews | ||
| 13:49 | XFRA X0M: WIEDERAUFNAHME/RESUMPTION | 241 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 13:36 | Ligand to buy XOMA Royalty for $39/share | 1 | Seeking Alpha | ||
| 13:25 | XFRA X0M: AUSSETZUNG/SUSPENSION | 152 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILXOMA ROY. PRF.SH.SER.A... ► Artikel lesen | |
| 13:22 | Ligand übernimmt XOMA Royalty für 739 Millionen US-Dollar in bar | 4 | Investing.com Deutsch | ||
| 13:18 | Ligand to acquire XOMA Royalty for $739 million in cash | 1 | Investing.com | ||
| 13:16 | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 13:00 | Ligand Pharmaceuticals: Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator | 78 | GlobeNewswire (Europe) | Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary... ► Artikel lesen | |
| 12:36 | Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ | 4 | Seeking Alpha | ||
| 02.04. | Dividendenbekanntmachungen (02.04.2026) | 18.924 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD 0,2501 EUR AKTIA BANK PLC FI4000058870 - 0,8 EUR ALICO INC US0162301040 0,05 USD 0,0431... ► Artikel lesen | |
| 18.03. | XOMA Preferred Shares Series A declares $0.5391 dividend | 5 | Seeking Alpha | ||
| 18.03. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 1 | Seeking Alpha | ||
| 18.03. | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 3 | GlobeNewswire (USA) | ||
| 18.03. | XOMA Royalty Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | XOMA Royalty Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | XOMA Q1 2026 slides: royalty receipts surge 68%, portfolio tops 120 assets | 2 | Investing.com | ||
| 18.03. | XOMA-Aktie legt um 7 % zu: Starke Lizenzeinnahmen treiben Gewinn und Umsatz über Erwartungen | 1 | Investing.com Deutsch | ||
| 18.03. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,650 | +0,34 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| VERADERMICS | 94,53 | +39,56 % | Veradermics, Inc - 8-K, Current Report | ||
| ERASCA | 19,655 | -8,54 % | Stifel raises Erasca stock price target to $30 on RAS program | ||
| BIONTECH | 87,55 | -2,67 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 2,055 | -59,15 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARCELLX | 115,07 | +0,03 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,390 | +1,40 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| INTELLIA THERAPEUTICS | 11,980 | +2,92 % | Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test | ||
| EVOTEC | 5,305 | -1,76 % | Eilmeldung am Abend: EVOTEC SE kurz vor Wendepunkt? | ||
| CUE BIOPHARMA | 19,000 | +10,02 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenAU000000BMG3 BMG Resources Ltd. 23.04.2026 AU0000466021 BMG Resources Ltd. 24.04.2026 Tausch 1:1AU000000KAI5 Kairos... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 129,91 | +0,73 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRYKER | 280,00 | +0,18 % | Following Stryker Cyberattack, Avatier Launches Identity Challenge Card to Protect Organizations When Standard Security Fails | New Solution Delivers the First Auto-Enrolled, Air-Gapped Multi-Factor Authentication (MFA) That Can Be Deployed Enterprise-Wide in a Single Day: No Devices, Apps, or Network Connectivity RequiredPLEASANTON... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,640 | +9,35 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,835 | +0,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| ALUMIS | 24,730 | -0,84 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen |
Das Unternehmen XOMA ROYALTY CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 20,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA ROYALTY CORPORATION PREF finden Sie auf Wallstreet Online.